Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) EPS (Basic): 2017-2025

Historic EPS (Basic) for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Sep 2025 value amounting to -$1.38.

  • Crinetics Pharmaceuticals' EPS (Basic) fell 43.75% to -$1.38 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.52, marking a year-over-year decrease of 21.83%. This contributed to the annual value of -$3.69 for FY2024, which is negligibly% changed negligibly from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' EPS (Basic) is -$1.38, which was down 12.20% from -$1.23 recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' EPS (Basic) registered a high of -$0.69 during Q1 2021, and its lowest value of -$1.38 during Q3 2025.
  • Over the past 3 years, Crinetics Pharmaceuticals' median EPS (Basic) value was -$0.94 (recorded in 2024), while the average stood at -$1.00.
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' EPS (Basic) rose by 4.95% in 2024, and later crashed by 43.75% in 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' EPS (Basic) (Quarterly) stood at -$0.71 in 2021, then fell by 16.90% to -$0.83 in 2022, then decreased by 6.02% to -$0.88 in 2023, then grew by 1.14% to -$0.87 in 2024, then tumbled by 43.75% to -$1.38 in 2025.
  • Its EPS (Basic) stands at -$1.38 for Q3 2025, versus -$1.23 for Q2 2025 and -$1.04 for Q1 2025.